Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation

Net Sales

Net Sales %Chg

Net Sales Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Selling, General, and Administrative Expenses

Selling, General, and Administrative Expenses %Chg

Selling, General, and Administrative Expenses Common Size

Research and Development Expenses

Research and Development Expenses %Chg

Research and Development Expenses Common Size

Certain Litigation Expenses

Certain Litigation Expenses %Chg

Certain Litigation Expenses Common Size

Change in Fair Value of Contingent Consideration Liabilities

Change in Fair Value of Contingent Consideration Liabilities %Chg

Change in Fair Value of Contingent Consideration Liabilities Common Size

Restructuring Charges and Separation Costs

Restructuring Charges and Separation Costs %Chg

Restructuring Charges and Separation Costs Common Size

Intangible Assets Impairment Charges

Intangible Assets Impairment Charges %Chg

Intangible Assets Impairment Charges Common Size

Other Operating Expense, Net

Other Operating Expense, Net %Chg

Other Operating Expense, Net Common Size

Operating Income, Net

Operating Income, Net %Chg

Operating Income, Net Common Size

Special Gain

Special Gain %Chg

Special Gain Common Size

Interest Income, Net

Interest Income, Net %Chg

Interest Income, Net Common Size

Special Charges (Gains)

Special Charges (Gains) %Chg

Special Charges (Gains) Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Other Income, Net

Other Income, Net %Chg

Other Income, Net Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Loss on Impairment

Loss on Impairment %Chg

Loss on Impairment Common Size

Other Non-Operating Income, Net

Other Non-Operating Income, Net %Chg

Other Non-Operating Income, Net Common Size

Income from Continuing Operations Before Provision for Income Taxes

Income from Continuing Operations Before Provision for Income Taxes %Chg

Income from Continuing Operations Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Net Income from Continuing Operations

Net Income from Continuing Operations %Chg

Net Income from Continuing Operations Common Size

Income from Discontinued Operations, Net of Tax

Income from Discontinued Operations, Net of Tax %Chg

Income from Discontinued Operations, Net of Tax Common Size

Net Income

Net Income %Chg

Net Income Common Size

Net Loss Attributable to Noncontrolling Interest

Net Loss Attributable to Noncontrolling Interest %Chg

Net Loss Attributable to Noncontrolling Interest Common Size

Net Income Attributable to Edwards Lifesciences Corporation

Net Income Attributable to Edwards Lifesciences Corporation %Chg

Net Income Attributable to Edwards Lifesciences Corporation Common Size

Continuing Operations

Continuing Operations %Chg

Continuing Operations Common Size

Discontinued Operations

Discontinued Operations %Chg

Discontinued Operations Common Size

Basic Earnings per Share

Basic Earnings per Share %Chg

Basic Earnings per Share Common Size

Diluted Earnings per Share

Diluted Earnings per Share %Chg

Diluted Earnings per Share Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	1,553.1	1,532.2	1,412.7	1,385.8	1,354.4	1,369.4
Total Revenues %Chg	14.7%	11.9%	6.2%	9.4%	8.9%	5.7%
Net Sales
Cost of Sales	345.2	344.4	301.6	292.2	262.9	275.5
Cost of Sales
Gross Profit	1,207.9	1,187.8	1,111.1	1,093.6	1,091.5	1,093.9
Gross Profit
Gross Profit Margin	77.8%	77.5%	78.7%	78.9%	80.6%	79.9%
Selling, General & Administrative Expenses	514.6	502	465.7	491.9	421.4	447.5
Selling, General, and Administrative Expenses
Research & Development Expenses	280.7	276.2	254.6	271.1	253.4	271.8
Research and Development Expenses
Other Operating Expenses	130.5	88.1	34.2	63.4	21.3	8.1
Certain Litigation Expenses
Change in Fair Value of Contingent Consideration Liabilities
Restructuring Charges and Separation Costs
Other Operating Expense, Net
Intangible Assets Impairment Charges
Loss on Impairment
Operating Profit	307.1	411.2	394.8	312.6	350.6	366.5
Operating Income, Net
Operating Margin	19.8%	26.8%	27.9%	22.6%	25.9%	26.8%
Non-Operating Income	-35.9	-85.8	-33.9	-10.9	3.6	-13.5
Special Gain
Special Charges (Gains)
Other Expense, Net
Other Income, Net
Loss on Impairment
Other Non-Operating Income, Net
Interest Income, Net
Total Non-Operating Income	-35.9	-85.8	-33.9	-10.9	3.6	-13.5
Income Before Provision for Income Taxes	348.4	400.2	433.9	390.1	402.8	384
Income from Continuing Operations Before Provision for Income Taxes
Provision for Income Taxes	56.1	64.3	70.3	45.1	40.7	20
Provision for Income Taxes
Consolidated Net Income	582.6	667.4	720	729.3	3,431.5	729
Net Income from Continuing Operations
Net Income
Net Income Attributable to Minority Interests and Other	-0.8	-1.7	-1.6	-1.3	-1.4	-1.3
Net Loss Attributable to Noncontrolling Interest
Net Income Attributable to Discontinued Operations	-2	-4.4	-7.2	39.3	2,707.3	1
Income from Discontinued Operations, Net of Tax
Net Income Attributable to Common Shareholders	291.1	333.2	358	385.6	3,070.8	366.3
Net Income Attributable to Edwards Lifesciences Corporation
Basic EPS	0.5	0.6	0.6	0.7	5.1	0.6
Diluted EPS	0.5	0.6	0.6	0.7	5.1	0.6
Basic Weighted Average Shares Outstanding	584.7	587	586.9	589.8	597.2	602.1
Total Shares Outstanding	580.7	587.9	586.2	588.6	589.8	602.3
Diluted Weighted Average Shares Outstanding	585.7	587.9	587.8	590.5	598.1	604.3
EBITDA	346.3	449.3	431.4	355.2	385.1	406.1
Effective Tax Rate	16.1%	16.1%	16.2%	11.6%	10.1%	5.2%